RVNC Overview
Upcoming Projects (RVNC)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (RVNC)
-
Examining a clinician's confidence in botox biosimilar clinical development programs
Tickers: VTRSV, AGN, RVNC
Executed On: Oct 14, 2022 at 08:30 AM EDT
Expired Projects (RVNC)
-
Discussing Revance Therapeutics’ DaxibotulinumtoxinA in Moderate to severe glabellar lines following PDUFA Approval
Ticker: RVNC
Execute By: Nov 17, 2022
Upcoming & Overdue Catalysts (RVNC)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (RVNC)
-
Revance's (RVNC) DAXI (RT002) - (ASPEN-1/ASPEN-OLS) in Cervical dystonia data to be presented at AAN meeting April 17-22, 2021
Ticker: RVNC
Occurred on: Apr 17, 2021 -
Revance's (RVNC) RT002 data from Pivotal SAKURA Phase 3 Trials for Glabellar Lines released
Ticker: RVNC
Occurred on: Dec 05, 2017 -
Revance Reports Results for RT001 Topical Phase 3 Trial for Lateral Canthal Lines
Ticker: RVNC
Occurred on: Jun 13, 2016 -
Phase 2 trial of RT001 for Hyperhidrosis to be completed 1Q 2016. Larger Phase 2 trial planned for 2016
Ticker: RVNC
Occurred on: Mar 02, 2016 -
Revance's (RVNC) RT002 Superior to Allergan's (AGN) BOTOX in Phase 2 Study Evaluating Treatment of Frown Lines
Tickers: RVNC, PFE, VRX, AGN
Occurred on: Oct 29, 2015
Strategic Initiatives (RVNC)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
